COlchicine in Cardiac Surgery

Atrial Fibrillation New Onset Clinical Trial

— COCS  

Official title:

Colchicine for Prevention Atrial Fibrillation After Cardiac Surgery in the Early Postoperative Period

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04224545
• Other study ID #: #2.20122019
• Status: Completed
• Phase: Phase 4
• Start date: December 23, 2019
• Est. completion date: August 23, 2022

Study information

• Verified date: February 2024
• Source: Bakulev Scientific Center of Cardiovascular Surgery
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. More researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions. This research is aimed to study the effectiveness of short-term administration of the drug.

Description:

Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Postoperative AF is considered as a multifactorial phenomenon. Its pathogenesis is characterized by inflammation, oxidative stress and autonomic dysfunction. Several predisposing factors lead to the development of POAF, including pre -, intra-and postoperative factors. The main of them are age, previous history of major cardiovascular risk factors and ischemic reperfusion injury during surgery. Treatment of POAF involves drugs to control the frequency of rhythm in hemodynamically stable patients and other treatment regimens usually used for the treatment of AF. Intraoperative administration of beta-blockers and some antiarrhythmic drugs is recommended by international clinical guidelines. In addition, previous treatment consisting of the use of colchicine, magnesium sulfate, statins and antioxidants have reduced the incidence of postoperative AF. However, the results of large-scale randomized trials have observed the development of undesirable adverse reactions. Despite these recommendations, the question of the correct regimen for prevention of POAF remains controversial. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. Two studies sequentially COPPS-1 and COPPS-2 evaluated the effect of colchicine on the incidence of POAF after open heart surgery (COPPS-1) and the development of postcardiotomy syndrome (COPPS-2). In COPPS-1, patients (n=336) were treated with colchicine from the third day after surgery for a month and showed a significant decrease of POAF after heart surgery over the entire follow-up period. 360 patients were evaluated in the COPPS-2 study. The incidence of POAF between the colchicine and placebo groups was comparable, although colchicine significantly reduced postpericardiotomy syndrome. The main limitation of the COPSS-2 study was the high rate of cessation of intervention (20% of participants), which had a significant impact on the outcome of the trial. Based on the latest meta-analysis of the colchicine effect on POAF after heart surgery, it was found that it still reduces POAF compared with control (HR = 0.69, 95% IM 0.57-0.84, p = 0.0002) and the duration of hospital stay was reduced by 1.2 days (95% IM -1.89 to -0.44, p = 0.002); however, the frequency of adverse gastrointestinal events increased significantly (HR = 2.52, 95% IM 1.62-3.93, p < 0.0001). Despite the high level of side effects, a significant reduction of POAF outweighs the balance in the favor of its use. However, more researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions. This research is aimed to study the effectiveness of short-term administration of the drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 267
• Est. completion date: August 23, 2022
• Est. primary completion date: August 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

Adult patients awaiting elective cardiac surgery (CABG and/or AVR (aortic valve replacement), who are willing and able to give informed consent for participation in the study and who are in sinus rhythm and not taking any antiarrhythmic medication, except beta-adrenergic blocking agents, at the time before surgery.

Exclusion Criteria:

• History of persistent or long-term atrial fibrillation/atrial flutter
• Congenital heart disease, except the bicuspid AV
• Frequent VE/SVE, AV block 2-3 degrees
• Use of corticosteroids during the last month
• Taking any antiarrhythmic drugs, except beta-blockers, within the last 1 month
• Prior "open" heart surgery
• Moderate to severe renal failure (creatinine clearance < 50 ml / min)
• History of obstructive hepato-biliary disease or other serious hepatic disease
• Significant mitral valve disease (moderate or severe mitral regurgitation-eg. > grade II and/or mitral stenosis & mitral annular calcification).
• Patient participation in another clinical trial

Related Conditions & MeSH terms

• Atrial Fibrillation
• Atrial Fibrillation New Onset
• Colchicine Adverse Reaction

Intervention

Drug:
• Colchicine Pill
Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
• Placebo
Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.

Locations

Country	Name	City	State
Russian Federation	Federal Center for Cardiovascular Surgery (Astrakhan)	Astrakhan
Russian Federation	Bakulev National Medical Research Center for Cardiovascular Surgery	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Bakulev Scientific Center of Cardiovascular Surgery

Country where clinical trial is conducted

Russian Federation, 

References & Publications (3)

Shvartz V, Le T, Enginoev S, Sokolskaya M, Ispiryan A, Shvartz E, Nudel D, Araslanova N, Petrosyan A, Donakanyan S, Chernov I, Bockeria L, Golukhova E. Colchicine in Cardiac Surgery: The COCS Randomized Clinical Trial. J Cardiovasc Dev Dis. 2022 Oct 20;9( — View Citation

Shvartz V, Le T, Kryukov Y, Sokolskaya M, Ispiryan A, Khugaeva E, Yurkulieva G, Shvartz E, Petrosyan A, Bockeria L, Bockeria O. Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period. J Clin Med. 2022 Mar — View Citation

Shvartz V.A., Le T.G., Enginoev S.T., Sokolskaya M.A., Ispiryan A.Yu., Shvartz E.N., Nudel D.V., Araslanova N.Kh., Petrosyan A.D., Talibova S.M., Donakanyan S.A., Chernov I.I., Bo?keria L.A., Golukhova E.Z. Association of new markers of systemic inflammat

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with postoperative atrial fibrillation.	POAF detected on continuous ECG monitoring.	Monitoring is carried out immediately after surgery and will be continued until the end of the 7th postoperative day.
Secondary	Number of participants with lethal and non-lethal events.	The main nosocomial lethal and non-lethal events (death, stroke, myocardial infarction, heart failure).	Participants will be followed for the duration of the postoperative period up to the day of initial discharge from the hospital, an expected average of 7 days.
Secondary	Fluid in the pericardium.	Fluid in the pericardium evaluated by echocardiography.	Diagnostics will be carried out on the 3rd and 5th day after surgery.
Secondary	Fluid in the pleura.	Fluid in the pleura evaluated by echocardiography.	Diagnostics will be carried out on the 3rd and 5th day after surgery.
Secondary	Acute kidney damage (according to the dynamics of creatinine clearance).	Dynamics of creatinine clearance.	Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.
Secondary	Inflammation in blood plasma.	Dynamics of biomarker of inflammation in blood plasma (neutrophils).	Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.
Secondary	Liver damage	Dynamics of biomarkers of liver damage (aspartate aminotransferase, alanine aminotransferase).	Diagnostics will be carried out a day before surgery and on the 3rd and 5th day after surgery.